433 related articles for article (PubMed ID: 24810875)
1. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
2. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
[TBL] [Abstract][Full Text] [Related]
4. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
5. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
[TBL] [Abstract][Full Text] [Related]
6. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
7. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
9. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
10. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
11. Targeted topical and combination laser surgery for the treatment of angiofibromas.
Bae-Harboe YS; Geronemus RG
Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
[TBL] [Abstract][Full Text] [Related]
12. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
[TBL] [Abstract][Full Text] [Related]
13. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
[TBL] [Abstract][Full Text] [Related]
14. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
Dao DD; Pixley JN; Akkurt ZM; Feldman SR
Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
[TBL] [Abstract][Full Text] [Related]
15. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
Park J; Yun SK; Cho YS; Song KH; Kim HU
Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
17. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
18. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
19. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
